Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of “Moderate Buy” by Analysts

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $19.00.

A number of analysts have commented on the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $14.00 target price (down from $23.00) on shares of Contineum Therapeutics in a report on Thursday, January 8th. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Royal Bank Of Canada lowered their price objective on shares of Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a report on Friday, November 21st. Leerink Partners assumed coverage on Contineum Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $22.00 price target for the company. Finally, Robert W. Baird decreased their target price on shares of Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, November 24th.

Contineum Therapeutics Stock Up 1.9%

NASDAQ:CTNM opened at $15.93 on Wednesday. The firm has a market cap of $464.84 million, a PE ratio of -7.08 and a beta of 1.18. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.33. The company’s 50-day moving average price is $12.93 and its two-hundred day moving average price is $11.66.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new position in Contineum Therapeutics in the 1st quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Contineum Therapeutics during the fourth quarter worth $43,000. Qube Research & Technologies Ltd bought a new position in shares of Contineum Therapeutics in the 2nd quarter valued at $43,000. Marex Group plc acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at $45,000. Finally, Bridgeway Capital Management LLC bought a new stake in Contineum Therapeutics during the 2nd quarter worth $76,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.